Supply Of 'Important' OTCs From EU Prioritized In Event Of No Deal Brexit
Executive SummaryIn preparation for a possible no deal Brexit, the UK government is prioritizing supply from the EU those OTC medicines deemed "important for the management of specific health conditions." The Department of Health and Social Care says it is continuing to work closely with OTC manufacturers and suppliers to prepare for Brexit.
You may also be interested in...
The UK has for decades been considered a European Rx-to-OTC switch leader. A combination of regulatory openness and a strong retail infrastructure will enable the country to remain so even if it leaves the European Union in October, insists the Proprietary Association of Great Britain's senior director of Regulatory Affairs, Michelle Riddalls, in an exclusive interview.
Labelling costs approaching £1.0m, import and export delays, and higher consumer prices are some of the many issues facing the food supplements industry in the event of a no deal Brexit, trade association CRN UK tells HBW Insight.
In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.